IDEXX Laboratories Receives FDA Approval of New EPM Treatment—NAVIGATOR®

WESTBROOK, Maine, November 19, 2003—IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market and sell NAVIGATOR® (32% nitazoxanide) Antiprotozoal Oral Paste, a new treatment for equine protozoal myeloencephalitis (EPM), a progressive, degenerative disease of the central nervous system that can cause serious or even fatal neurological problems in horses.

"NAVIGATOR Paste is a powerful new treatment for this potentially devastating disease," commented IDEXX President and CEO Jonathan Ayers. "NAVIGATOR is a significant component of our strategy to provide innovative diagnostic and therapeutic solutions to equine veterinarians."

IDEXX Laboratories, Inc., is a worldwide leader in the development and commercialization of innovative, technology-based products and services for animal health. The Company's largest business is focused on companion animal health, combining biotechnology, medical device technology and information technology to aid veterinarians in providing better medicine while building successful practices. IDEXX Laboratories is also focused on employing innovative technologies to monitor production animal health and the safety and quality of drinking water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs over 2,400 people and offers products to customers in more than 100 countries.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations of future events, which are subject to risks and uncertainties. If underlying assumptions prove inaccurate, actual results could vary materially from management's expectations. Risks and uncertainties include timing and success of new product introductions, competition and technological change, government regulation and obtaining government approvals, product demand and market acceptance, availability of products and raw materials, and litigation. A further description of these risks and uncertainties and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2002 (PDF, 350 KB) and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2003 (PDF, 2,277 KB), in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations." The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

 

---

Please consult the package insert for more information.

---